The best-funded Dutch biotech and life sciences startups of 2026

The Dutch biotech and life sciences sector is attracting investors across a wide range of stages and segments. From molecular tumour models in Groningen to an eClinical platform with nearly sixty million euros raised in Amsterdam: the spread is considerable, both in funding size and technological approach.

A recurring theme among the better-funded players is the combination of wet biology with machine learning. This makes the companies recognisable to investors seeking scalable methods in a sector that has traditionally been capital-intensive and slow-moving. At the same time, the label 'AI in biotech' no longer differentiates companies from one another: what matters is how concretely the technology contributes to clinical or commercial outcomes.

Ten recently funded Dutch companies offer a picture of where the money is going and what is attracting investors and grant providers.

Cradle and Genzai at the top in terms of size

Amsterdam-based Cradle raised a €100 million Series B in 2024. The company, founded in 2021, combines machine learning with its own wet-lab research to accelerate protein design. A round of that size is unusual for a Dutch startup at this stage and reflects the international interest in computational biology as an accelerator of drug development.

Even larger is the funding position of Venlo-based Genzai, which has raised €333 million. Genzai combines AI implementation with venture capital, targeting measurable returns at mid-sized companies in sectors including agri-food and life sciences. The scale of this round illustrates that hardware development and broad platform strategies require significantly more capital than sector-specific software tools.

Clinical software and data analysis as a stable middle tier

Castor EDC (Amsterdam, founded 2012) is building an eClinical platform that simplifies clinical studies. The company raised a Series B of €59.8 million in 2021, one of the larger rounds in the Dutch life sciences software space. Its approach focuses on accelerating data collection and management in clinical research, a segment where international pharma and biotech companies are actively seeking more efficient workflows.

Nijmegen-based Saddle Point Science (founded 2022) is working on Bayesian data analysis for more precise treatment outcomes and received €17.5 million in grant funding. Public financing of this magnitude indicates that the methodology aligns with the research priorities of funds aiming to accelerate precision medicine.

InnoSIGN (Eindhoven, 2021) translates multi-omics data into insights for treatment decisions and raised a Series A of €8 million. CytoSMART Technologies (Eindhoven, 2012) builds miniature microscopes for real-time cell monitoring and has raised €5.2 million through a Series B.

Early stage: cancer, channelopathies and single-cell

Three Nijmegen-based companies are at an earlier funding stage, but are targeting specific scientific niches that appeal to investors. Synaptica (founded 2022) is developing machine learning tools for personalised treatment of channelopathies, rare conditions in which ion channels in cells do not function properly. The company raised €3 million in a venture round.

QurieGen (2022) uses single-cell technology to accelerate drug discovery and target identification, and closed a seed round of €2.2 million in early 2025. Groningen-based Protyon (2022) uses molecular tumour models to predict which cancer therapy will work for an individual patient. The company is still in the pre-seed stage, having raised €600,000.

The fact that three of these early-stage players are based in Nijmegen is connected to the proximity of Radboudumc and the research infrastructure of Radboud University, which serves as an incubator for spin-offs in molecular biology and neurology.

Bioinformatics with limited external funding

ENPICOM ('s-Hertogenbosch, 2015) applies bioinformatics and machine learning to accelerate the discovery of biologics. With €1.3 million at Series B stage, external funding is relatively limited, which may point to bootstrap-style growth or to service revenues that reduce the need for external capital. The company focuses on immunome analysis, a specific sub-field within the broader bioinformatics market.

What attracts investors in this segment

Looking at the ten companies, a few patterns stand out. First, the combination of proprietary data generation with algorithmic processing attracts larger rounds: Cradle does this explicitly through its wet-lab component, while InnoSIGN and QurieGen build proprietary datasets through specific measurement methods. Second, clinical applications with a clear path to regulatory approval, such as Castor EDC's platform for clinical studies, are attractive to later-stage investors looking for predictable revenue models.

Third, the presence of a large grant round at Saddle Point Science shows that public funding is a fully viable strategy for methodological research that is too early for venture capital but too innovative for traditional academic budgets.

For the broader Dutch and European AI and life sciences scene, these ten companies confirm that the sector is maturing: clearer funding ladders are visible, from pre-seed in Groningen to Series B in Amsterdam and Eindhoven. At the same time, the challenge remains that much of the value is still locked in early research stages, with long timelines for clinical validation. Investors and policymakers who want more of these companies to scale to later stages within the Netherlands are looking at a sector that benefits from both patient capital and access to clinical networks.